VRTX

SEC source: 0001209191-23-042566 · doc4.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,553

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $355.54 (range $355.00 to $355.97).

SEC source: 0001209191-23-042566 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-042563 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,656.448

Underlying: Common Stock · 89.927 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

SEC source: 0001209191-23-042566 · doc4.xml · derivative · entry 5

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,524.966

Underlying: Common Stock · 124.719 shares

Expires not disclosed

F6 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F6 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F6 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

SEC source: 0001209191-23-038343 · doc4.xml · derivative · entry 4

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,603

Underlying: Common Stock · 8,603 shares

Expires 2029-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-23-038343 · doc4.xml · nonDerivative · entry 2

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,556

F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.

F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $349.00 (range $349.00 to $349.02).

SEC source: 0001209191-23-038343 · doc4.xml · nonDerivative · entry 1

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,159

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-033312 · doc4.xml · nonDerivative · entry 1

Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,838

F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.

SEC source: 0001209191-23-033321 · doc4.xml · nonDerivative · entry 1

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,556

F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.

SEC source: 0001209191-23-028240 · doc4.xml · nonDerivative · entry 3

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,387

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022.

SEC source: 0001209191-23-028243 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,038

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

SEC source: 0001209191-23-028240 · doc4.xml · nonDerivative · entry 2

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,512

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $350.30 (range $350.12 to $350.40).

SEC source: 0001209191-23-028240 · doc4.xml · nonDerivative · entry 1

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,683

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $349.38 (range $349.00 to $349.95).

SEC source: 0001209191-23-028243 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,888

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $350.03 (range $350.00 to $350.40).

SEC source: 0001209191-23-027372 · doc4.xml · nonDerivative · entry 6

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,391

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F8 · price: Open market sales reported on this line occurred at a weighted average price of $351.59 (range $351.33 to $352.02).

SEC source: 0001209191-23-027372 · doc4.xml · nonDerivative · entry 5

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,091

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F7 · price: Open market sales reported on this line occurred at a weighted average price of $350.53 (range $350.08 to $350.90).

SEC source: 0001209191-23-027372 · doc4.xml · nonDerivative · entry 4

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,891

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F6 · price: Open market sales reported on this line occurred at a weighted average price of $349.22 (range $349.00 to $349.94).

SEC source: 0001209191-23-027374 · doc4.xml · nonDerivative · entry 5

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,310

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F7 · price: Open market sales reported on this line occurred at a weighted average price of $351.60 (range $351.01 to $352.00).

SEC source: 0001209191-23-027374 · doc4.xml · nonDerivative · entry 4

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,038

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F6 · price: Open market sales reported on this line occurred at a weighted average price of $350.44 (range $350.00 to $350.94).

SEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 6

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,628

F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022.

F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F8 · price: Open market sales reported on this line occurred at a weighted average price of $351.20 (range $350.92 to $351.48).

SEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 5

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,691

F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022.

F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F7 · price: Open market sales reported on this line occurred at a weighted average price of $349.82 (range $349.17 to $350.08).

SEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 4

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,854

F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022.

F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F6 · price: Open market sales reported on this line occurred at a weighted average price of $348.16 (range $347.91 to $348.64).

SEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 3

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,974

F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022.

F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $346.69 (range $346.31 to $347.03).

SEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 2

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,146

F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022.

F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $345.93 (range $345.20 to $346.12).

SEC source: 0001209191-23-027372 · doc4.xml · nonDerivative · entry 3

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,899

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $353.18 (range $352.63 to $353.53).

SEC source: 0001209191-23-027372 · doc4.xml · nonDerivative · entry 2

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,199

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $350.48 (range $350.08 to $351.01).

SEC source: 0001209191-23-027372 · doc4.xml · nonDerivative · entry 1

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,704

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $349.48 (range $349.00 to $349.99).

SEC source: 0001209191-23-027374 · doc4.xml · nonDerivative · entry 3

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,091

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $353.24 (range $353.21 to $353.49).

SEC source: 0001209191-23-027374 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,260

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $351.65 (range $351.48 to $351.80).

SEC source: 0001209191-23-027374 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,302

F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.

F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $350.32 (range $350.00 to $350.92).

SEC source: 0001209191-23-026991 · doc4.xml · nonDerivative · entry 1

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,208

F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

SEC source: 0001209191-23-027002 · doc4.xml · nonDerivative · entry 1

CARNEY LLOYD · CIK 0001204424 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,318

F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

SEC source: 0001209191-23-027015 · doc4.xml · derivative · entry 2

Garber Alan M · CIK 0001312907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,741

Underlying: Common Stock · 1,741 shares

Expires 2033-04-30

F2 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-23-027015 · doc4.xml · nonDerivative · entry 1

Garber Alan M · CIK 0001312907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,474

F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

SEC source: 0001209191-23-027028 · doc4.xml · derivative · entry 1

Kearney Terrence C · CIK 0001289098 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,481

Underlying: Common Stock · 3,481 shares

Expires 2033-04-30

F1 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-23-027034 · doc4.xml · derivative · entry 1

Lee Yuchun · CIK 0001334365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,481

Underlying: Common Stock · 3,481 shares

Expires 2033-04-30

F1 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-23-027038 · doc4.xml · derivative · entry 1

MCGLYNN MARGARET G · CIK 0001215126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,481

Underlying: Common Stock · 3,481 shares

Expires 2033-04-30

F1 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-23-027051 · doc4.xml · derivative · entry 4

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,566.521

Underlying: Common Stock · 1,449 shares

Expires not disclosed

F3 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2022, Ms. McKenzie deferred the receipt of 1,449 shares of common stock and received instead 1,449 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,449 shares of common stock in exchange for an equal number of deferred stock units.

F3 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F3 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

SEC source: 0001209191-23-027051 · doc4.xml · nonDerivative · entry 2

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,603

F2 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

SEC source: 0001209191-23-027051 · doc4.xml · nonDerivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,435

F1 · price: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2022, Ms. McKenzie deferred the receipt of 1,449 shares of common stock and received instead 1,449 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,449 shares of common stock in exchange for an equal number of deferred stock units.

SEC source: 0001209191-23-027056 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,481

Underlying: Common Stock · 3,481 shares

Expires 2033-04-30

F1 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-23-027060 · doc4.xml · nonDerivative · entry 1

Upadhyay Suketu · CIK 0001533149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,726

F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

SEC source: 0001209191-23-026270 · doc4.xml · nonDerivative · entry 3

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,652

F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022.

SEC source: 0001209191-23-026270 · doc4.xml · nonDerivative · entry 2

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,690

F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022.

F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $339.43 (range $339.00 to $339.98).

SEC source: 0001209191-23-026270 · doc4.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,358

F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022.

F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $338.69 (range $338.00 to $338.99).

SEC source: 0001209191-23-024705 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,117.521

Underlying: Common Stock · 90.153 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

SEC source: 0001209191-23-024711 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,400.247

Underlying: Common Stock · 131.473 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

SEC source: 0001209191-23-024305 · doc4.xml · nonDerivative · entry 5

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

SEC source: 0001209191-23-024305 · doc4.xml · derivative · entry 6

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,300 shares

Expires 2024-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Fully vested

SEC source: 0001209191-23-024305 · doc4.xml · nonDerivative · entry 4

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,210

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $327.48 (range $327.00 to $327.93).